Med-Psych Drug-Drug Interactions Update Triptans
... These modest findings reflect almotriptan’s multiple avenues of metabolism, which allow the drug to be biotransformed despite “roadblocks” at some of its metabolic sites. We could not find case reports or studies concerning triptan use with potent 3A4 inhibitors. We suspect that more potent inhibito ...
... These modest findings reflect almotriptan’s multiple avenues of metabolism, which allow the drug to be biotransformed despite “roadblocks” at some of its metabolic sites. We could not find case reports or studies concerning triptan use with potent 3A4 inhibitors. We suspect that more potent inhibito ...
Additivity Versus Synergy: A Theoretical Analysis of - Area-c54
... BACKGROUND: Inhaled anesthetics have been postulated to act at multiple receptors, with modest action at each site summing to produce immobility to noxious stimulation. Recent experimental results affirm prior findings that inhaled anesthetics interact additively. Synergy implies multiple sites of a ...
... BACKGROUND: Inhaled anesthetics have been postulated to act at multiple receptors, with modest action at each site summing to produce immobility to noxious stimulation. Recent experimental results affirm prior findings that inhaled anesthetics interact additively. Synergy implies multiple sites of a ...
Product Monograph - Ask Novartis Pharma
... clearance of uric acid and may cause or exacerbate hyperuricemia and precipitate gout in susceptible patients. Thiazides are contraindicated in patients with symptomatic hyperuricemia. Thiazides decrease urinary calcium excretion and may cause mild elevation of serum calcium in the absence of known ...
... clearance of uric acid and may cause or exacerbate hyperuricemia and precipitate gout in susceptible patients. Thiazides are contraindicated in patients with symptomatic hyperuricemia. Thiazides decrease urinary calcium excretion and may cause mild elevation of serum calcium in the absence of known ...
Losartan Potassium
... antagonist. It is the first of a new class of drugs to be introduced for clinical use in hypertension. This novel agent binds competitively and selectively to the AII subtype 1 (AT1) receptor, thereby blocking AII-induced physiological effects. An active metabolite, E3174, contributes substantially ...
... antagonist. It is the first of a new class of drugs to be introduced for clinical use in hypertension. This novel agent binds competitively and selectively to the AII subtype 1 (AT1) receptor, thereby blocking AII-induced physiological effects. An active metabolite, E3174, contributes substantially ...
Sedative-Hypnotic Drugs
... – Hypnotic/anxiolytic effect discovered in the early 20th century (Veronal®, 1903) – Until the 60s the largest group of hypnotics (more hypnotic than anxiolytic) – Act by both enhancing GABA responses and mimicking GABA (open Cl-channels in the absence of GABA) => increased inhibition of the CNS (al ...
... – Hypnotic/anxiolytic effect discovered in the early 20th century (Veronal®, 1903) – Until the 60s the largest group of hypnotics (more hypnotic than anxiolytic) – Act by both enhancing GABA responses and mimicking GABA (open Cl-channels in the absence of GABA) => increased inhibition of the CNS (al ...
